This 12-week randomised, placebo-controlled phase 1b study evaluated the safety, tolerability, pharmacokinetics and efficacy of IBI362, a novel weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity. Here, GCG is linked to obesity disorder.